Nghĩa của từ T cell antigen receptor bằng Tiếng Việt
danh từ
thụ thể tế bào T dành cho kháng nguyê
Đặt câu có từ "T cell antigen receptor"
1. Chimeric Antigen Receptor (CAR) T-cell Therapy
2. T-Cell Clonality; T cell antigen receptors, Gene Rearrangement; Laboratory
3. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell
4. Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
5. Upon contact with its specific antigen, the T cell receptor transduces an activation signal into the T cell, leading to proliferation, cytokine production, or efficient cytotoxicity.
6. The Company develops Allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors.
7. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor …
8. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T-cell (CAR T
9. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T
10. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor structure and function; we also provide an introduction to T cell receptor genomics and the concept of the T cell clonotype.
11. Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors
12. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
13. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
14. Adoptive T-cell therapies with T-cells modified with chimeric antigen receptors (CAR-T) also causes CRS.
Điều trị miễn dịch ung thư bằng tế bào T đã được sửa đổi có các thụ thể kháng nguyên chimeric (CAR-T) cũng gây ra CRS.
15. A molecule that is capable of binding to an antibody or to an Antigen receptor on a T cell, especially one that induces an immune response
16. An Antigen-specific B cell antibody specifically recognizes a TI-2 Antigen, but without T cell help, a memory response is not seen.
17. Such Bulged pMHC-I complexes represent challenges for T-cell receptor (TCR) ligation, although t …
18. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
19. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
20. As with B cells, each type of T cell recognizes a different antigen.
Giống như các tế bào B, mỗi loại tế bào T nhận ra một kháng nguyên khác nhau.
21. Clone REA643 recognizes the mouse Allergin-1 antigen, a single-pass transmembrane protein also known as mast cell antigen 32 or allergy inhibitory receptor 1
22. The diagram above represents the process of Chimeric antigen receptor T-cell therapy (CAR), this is a method of immunotherapy, which is a growing practice in the treatment of cancer
23. CD8+ (Cytotoxic) T cells, like CD4+ Helper T cells, are generated in the thymus and express the T-cell receptor
24. The French biotech Servier has an agreement with Allogene Therapeutics, through Pfizer, to market its Allogenic chimeric antigen receptor (CAR) T-cell product in the United States if it receives
25. Anergy is characterised by decreased or absent lymphokine secretion by viable T cells when the T cell receptor is engaged by an antigen; it can be tested by loss of delayed hypersensitivity (e.g., to PPD, Candida antigens or DCNB).